key: cord-1003873-d2c171vz
authors: Kumar, Avinash; Parihar, Arpana; Panda, Udwesh; Parihar, Dipesh Singh
title: Microfluidics-Based Point-of-Care Testing (POCT) Devices in Dealing with Waves of COVID-19 Pandemic: The Emerging Solution
date: 2022-04-27
journal: ACS Appl Bio Mater
DOI: 10.1021/acsabm.1c01320
sha: 5efe14b91a6224791d9f3281dd93042430b8c8e7
doc_id: 1003873
cord_uid: d2c171vz

[Image: see text] Recent advances in microfluidics-based point-of-care testing (POCT) technology such as paper, array, and beads have shown promising results for diagnosing various infectious diseases. The fast and timely detection of viral infection has proven to be a critical step for deciding the therapeutic outcome in the current COVID-19 pandemic, which in turn not only enhances the patient survival rate but also reduces the disease-associated comorbidities. In the present scenario, rapid, noninvasive detection of the virus using low cost and high throughput microfluidics-based POCT devices embraces the advantages over existing diagnostic technologies, for which a centralized lab facility, expensive instruments, sample pretreatment, and skilled personnel are required. Microfluidic-based multiplexed POCT devices can be a boon for clinical diagnosis in developing countries that lacks a centralized health care system and resources. The microfluidic devices can be used for disease diagnosis and exploited for the development and testing of drug efficacy for disease treatment in model systems. The havoc created by the second wave of COVID-19 led several countries’ governments to the back front. The lack of diagnostic kits, medical devices, and human resources created a huge demand for a technology that can be remotely operated with single touch and data that can be analyzed on a phone. Recent advancements in information technology and the use of smartphones led to a paradigm shift in the development of diagnostic devices, which can be explored to deal with the current pandemic situation. This review sheds light on various approaches for the development of cost-effective microfluidics POCT devices. The successfully used microfluidic devices for COVID-19 detection under clinical settings along with their pros and cons have been discussed here. Further, the integration of microfluidic devices with smartphones and wireless network systems using the Internet-of-things will enable readers for manufacturing advanced POCT devices for remote disease management in low resource settings.

In the year 2019, a chain of acute atypical respiratory disorders came about in the metropolis of China. It quickly spread from Wuhan to different regions. It has been quickly revealed that a unique coronavirus became the reason. The novel coronavirus was named due to the extreme acute metabolism syndrome coronavirus-2 (SARS-CoV-2) and excessive similarity (∼80%) to SARS-CoV-2, which brought on acute respiratory distress syndrome and excessive mortality from 2002 to 2003. 1 It is believed that the SARS-CoV-2 infection initially originated in bats and was transmitted through animals than to humans associated with the food market in Wuhan city of China. Then later it was identified that human-to-human transmission competed for the main role in the succeeding outbreak. 2 The sickness because of this virus is named Coronavirus sickness (COVID- 19) , and it is considered a deadly disease. This name was declared with the aid of the World Health Organization. COVID-19 has affected a huge population worldwide, being pronounced in over one-hundred international locations and territories. 3, 4 Globally, as of February 25, 2022, there are 430 257 564 confirmed instances of COVID-19, collectively with 5 922 049 deaths as per a WHO report. 5 Various diagnostic techniques for the detection of this disease that are currently being used are shown in Figure 1 .

The difficulty of tracking and controlling COVID-19 infections globally is nonetheless unsatisfactory and limited because of a deficiency of responsible caretakers, medical centers, and the shortness of diagnostic equipment, vaccines, and capsules to control the contamination. Recently, some animals and humans have been observed constantly to understand the COVID-19 pathogenesis for facilitating the healing and vaccine discovery. Until then, to prevent COVID-19 infection, the best alternatives that someone can implement as controllable measures are inclusive life at home, hygiene, use of mask, maintaining social distancing, carrying out yoga, holding suitable immunity, etc. 6 The role of diagnostic tests to detect SARS-CoV-2 infection is crucial to not only identify the infectious agent but also decide the quarantine period to further stop the infection chain. In the present COVID-19 pandemic, rapid and prompt diagnosis of viral infection has proven to be a significant step in determining therapy outcomes, which not only improves patient survival but also reduces disease-related comorbidities. Rapid, noninvasive viral detection using low-cost, high-throughput microfluidics-based POCT devices offers advantages over existing diagnostic technologies, which require a centralized lab facility, expensive tools, sample pretreatment, and skilled employees. The second wave of COVID-19 wreaked havoc on several countries' governments, forcing them to retreat. Because diagnostic kits, medical devices, and human resources are in short supply, there is a need for technology that can be operated remotely with a single touch and data that can be analyzed on a phone. Recent advances in information technology and the widespread usage of smartphones have resulted in a paradigm change in the creation of diagnostic equipment that can be used to combat the present pandemic. This article discussed numerous ways for developing low-cost microfluidics POCT devices. The merits and cons of successfully employing microfluidic systems for COVID-19 detection in clinical settings have been discussed here. Furthermore, a brief insight over Internet-of-Things enabled POCT devices for remote disease management in low-resource settings by integrating microfluidic devices with smartphones and wireless network systems have been presented.

As predicted by many researchers, human beings around the world have seen the rise of COVID-19 instances in various countries in which the epidemic first emerged. The new waves of COVID-19 emerged with a high incidence of deaths, suggesting that the present diagnostic techniques or extended sources have failed to detect variants of SARS-CoV-2. Larger heterogeneous nations like the United States and Brazil, where the COVID-19 associated death rate is much higher, appear to revel in a mixture among the nevertheless ongoing first wave and a probable second wave coming from nearby geographic regions. One can hypothesize that older people are much more susceptible to this new epidemic wave. On the other hand, with the first wave of the ailment, more youthful people had been no longer located to be symptomatic and this would lead to unexpected considerations. SARS-CoV-2 has a large spectrum of ailments and symptoms. It has been identified that maximum infections are asymptomatic or oligosymptomatic. The degree of severity of the disease depends on underlining fitness conditions, sex, and age. It is likewise recognized that even though effective, the neutralizing antibodies may also decay fast, permitting hosts to be reinfected with coronavirus in a brief length of time. The first confirmed case of SARS-CoV-2 reinfection ended in much less symptomatic contamination in assessment to the primary episode of infection; however, next reinfection instances may also bring about a greater excessive consecutive second infection. 7−9 While seeking to develop a vaccine for intense acute respiratory syndrome and the Middle East respiratory syndrome, it is been detected a phenomenon named antibody-mediated immune reaction enhancement, which makes the symptoms more severe in patients. 10, 11 Therefore, the second and consecutively the third wave of COVID-19 infections may also constitute many reinfection instances. Because of the second wave, many more young people have been inflamed all through the primary wave of the infection, which is being misdiagnosed because the first infection became asymptomatic or oligo-symptomatic. As particular immunity waned or the virus was mutated due to antigenic drift, those uncovered younger people would possibly act as a new prone population to reload the epidemic, the second infection being more symptomatic or intense. Because of varied immune ACS Applied Bio Materials www.acsabm.org Review responses to SARS-CoV-2, such as heterogeneous antibodymediated immune reactions, it is hard to apply serologic tests for seroprevalence studies. Although the length of viral dropping can be better among asymptomatic people, as much as 40% of asymptomatic people will produce IgG in comparison to 12.9% of symptomatic instances. The decay of normal IgG or neutralizing antibodies is rapid in symptomatic and asymptomatic people. 12 It is more likely that a few infected people will now have no longer increased protective immunity or they need a couple of infections to increase protection. On a normal note, the second wave of COVID-19 hit the countries that had eased the regulations and no longer took the proper precautions for the future. Quarantine measures had wide-ranging and probably durable mental illness impacts on the overall population, in particular, wherever it lasted for several months. 13, 14 Indeed, psychiatric records showed a threat element for experiencing tension signs, symptoms, and anger 4−6 months after uplifting of quarantine. 15−17 Being quarantined entails dropping everyday workouts and a lack of private and social contacts that make life difficult and offer mental illness, and it comes with big prices for people with intellectual illnesses. There is a pressing need to keep away from letting techniques get used to mitigate the symptoms of COVID-19 patients struggling with psychiatric disorders. Now, more than ever, greater assistance is needed for this huge and inclined populace. 18 The SARS-COV-2 epidemic began in Wuhan, China, with the first patient appearing in December 2019; nevertheless, the first wave was discovered globally in March 2020. The fundamental reasons for this wave are still unknown. The first wave was seen as a calamity that severely impacted every aspect of life, posed a serious problem in public health, and disrupted social and economic activity worldwide. For instance, the global economy was harmed; goods production was almost halted in all regions, and the jobless rate skyrocketed. Another societal issue emerged such as increasing family violence among youngsters as a result of their prolonged stay at home. 19, 20 The third wave of COVID-19 saw various alterations and distinct traits including an increase in affected people owing to home contact. Furthermore, the widespread availability of fast antigen testing assays in early detection and isolation in case of severe infections lowered the fatality rates compared to the previous waves. The identification of a novel strain (B.1.1.7) with increased potential transmissibility was the most significant aspect of this wave; as a result, reinfections became more prevalent. These mutations that developed inside the virus may be the primary cause of the third wave, along with social activities between persons who did not take necessary safeguards. Vaccination, on the other hand, yielded excellent effects among patients, health care personnel, and the elderly. 21 Table 1 briefly compares the different waves and their effects on the world.

SARS-CoV-2 has a strong propensity for evading transmission barriers, especially when illnesses are prevalent. Coronavirus mutations are thought to be an ideal step for immunological escape. This might happen with partial resistance at first but with superior resistance, if coronavirus strains reinfection occurs. It is worth noting that the higher the infection rate, the greater the likelihood of mutations. This way, the virus will be able to survive and spread. Virus spread remains uncontrollable until we attain herd immunity without imposing constraints. The introduction of N501Y mutants recently connected with super spreading events and epidemics has seen boosted transmissibility. Surprisingly, the variant was first identified in Denmark among sick minks, but its appearance in other places suggests that it may spread independently from such animals. This mutation enhanced SARS-COV-2's capacity to attach to the human receptor angiotensin-converting enzyme 2 (ACE2), thereby accelerating the spread of the COVID-19 pandemic. 22 The variants that have lately emerged are omicron (B.1.1.529) in South Africa and delta in India (lineage B.1.1617). The first delta case was reported in October 2020, and the variant has a higher incidence of transmission and infection than other previously discovered variants. 23, 24 However, omicron was identified on November 9, 2021. The omicron variant was differentiated by its high diffusion speed and the transmission rate that is significantly higher than that of previous variants due to the increased number of mutations. The omicron variant's large number of mutations in the S protein may boost the virus's capacity to resist infectionblocking antibodies and other immune responses such as the T cell response. This result is consistent with preliminary evidence indicating a higher risk of reinfection with omicron compared to other strains, but data are still limited. The multiple mutations in spike protein, more than 30 changes in the viral region, are crucial for the virus's entry into human cells, according to early research. These omicron alterations have also been found in prior COVID-19 strains, including alpha and delta variants. However, numerous omicron mutations have not previously been identified, necessitating more research. The number of alterations was double compared to the delta variant. 25, 26 The RBD of the omicron variant had ten alterations, whereas delta variants had just two. According to recent research, the virus's mutation group (H655Y, N679 K, P681H) is connected with increased entry ability to the human cell, implying enhanced transmissibility. Furthermore, R203 K and G204R alterations were previously discovered in the alpha strain and also in the omicron strain, and these mutations increased infection rates.

However, there is presently no evidence that omicron symptoms vary from those of other strains. Initially, infections were detected among younger persons (university students) who had a lesser illness. Understanding the total degree of sickness caused by omicron will take several days if not weeks. According to an African Medical Association study, omicron is seven-times more infectious than the delta version, although recorded cases and fatalities in Africa have continued to fall, and those infected with omicron did not experience any major worsening of their health. 27 4. LIMITATIONS OF CURRENTLY AVAILABLE DIAGNOSTIC TECHNOLOGY Currently, a "medical analysis" of COVID-19 is being carried out by chest CT and RT-PCR. Other than in a clinical context, RT− PCR testing accounts for the largest proportion of surveillance testing carried out at administrative facilities or schools. However, due to poorly scheduled specimen collection and poor specimen handling, the chances of false results increased. Further, the need for experienced laboratory workers, long wait times to get results, and the need for expensive instruments, the nucleic acid amplification-based RT-PCR can be complicated in resource-poor settings. The typical RT-PCR is time-consuming, but it is no longer as timeconsuming as the time it takes to transport the specimens to the laboratory, which might take days. RT-PCR results additionally rely closely on the sort of sampling processes such as oropharyngeal swabs (32−48%), nasopharyngeal swabs (63%), bronchoalveolar lavage fluid (79−93%), sputum (72− 76%), and stool (29%). 28 Further, the scarcity of primers and other reagents needed to conduct the tests limits its further use. 29 New diagnostics are being intensively developed to overcome the limitations of RT-PCR. Investigations are ongoing to evaluate the efficacy of these tests, however limited. Present predicaments for immunodiagnostic procedures encompass a loss of specificity, that is, connected to false positive and false negative results due to closely associated strains of SARS-CoV-2 and cross-reactions with autoantibodies in autoimmune diseases. Immunodiagnostic assays can provide reliable results only after 7 to 11 days of infection and are consequently much less beneficial in the analysis of acute infection. 30 Outside the physical confines of the testing platform, data generated by nucleic acid amplification and serology testing fail to capture critical SARS-CoV-2 parameters such as the length of time a person is infectious or the prevalence of positive haplotypes in a community. Combining metagenomic detection techniques with nucleic acid amplification approaches might give new understandings to physicians and epidemiologists. Although RT-PCR is the current standard for detecting viral nucleic acids, new methods such as pulse-managed amplification are also being investigated. Pulse-managed amplification may not require ribonucleic acid extraction and can be completed in 10 min using a small instrument. 31 In the future, S-and N-based immunodiagnostic methods will be used in conjunction with nucleic acid amplification tests to improve SARS-CoV-2 detection sensitivity at a low cost. 32 Future efforts in the direction of the improvement of novel diagnostic systems might also be productive if the assessments are correct, particular, and smooth to run, generate results in a brief time, and are reasonably priced for mass-production. Given each of the strengths and boundaries of modern-day diagnostics and their singular output values, the results must be cautiously scrutinized before making choices on therapeutics in medical and nonmedical settings. It is likewise vital to recollect different techniques consisting of low-cost mass pooling and metagenomic profiling to expect futuristic outbreaks. COVID-19 prevention, detection, management, and treatment are all intertwined, and each aspect of COVID-19 control has an impact over the others. The proper and initial testing of COVID-19 is important to lower the danger of spreading of disease via permitting isolation and getting in touch with tracing. Consequently, the maximum big public health effect comes from the speedy finding of inflamed patients. Clinical findings of SARS-CoV-2 are based totally on medical signs and symptoms and records of touch with probably infected people.

Since the medical manifestations and symptoms of patients (pneumonia, dyspnoea, fever, cough, and respiration signs and symptoms) are not definitive, the role of diagnostic and serological tests is critical for the analysis of SARS-CoV-2. 33 The cost of clinic strategies relies upon the type of test, the time for results, accuracy of assay, and the specified sources for testing. In other words, the fast identity of suspected people is the primary approach to follow suitable timely measures and restrict spread. A pictorial depiction of the most commonly used diagnostics for SARS-CoV-2 is presented in Figure 2 .

Approaches. An assay to measure the antibody-mediated immune response against viral agents is called serological testing. 35 However, this method cannot identify current viral infection but determines whether or not a person is or has been infected via means of figuring out an antibody immune reaction against infections. Since these assays no longer dictate the early stage of contamination, the European Centre for Disease Prevention and Control (ECDC) has encouraged COVID-19 serological testing to be done solely for epidemiological and monitoring purposes. 36 Detection of previous infections even without testing out the ailment is feasible with these strategies and is the principal advantage of serological methods. Numerous serological tests are available for the detection of SARS-CoV-2, many of which have been advertised as POC and fast strategies. However, the accuracy of these POC tests continues to be challenging. 37 The serological assays of SARS-CoV-2 detect ranges of numerous immunoglobulin, which is in response to combat SARS-CoV-2 infection. A fast serological assay is a cellular nonautomatic approach for comparing membrane-based immunoassays and providing qualitative data quickly (approximately 5−20 min). The advantages encompass less sample volume (a small blood group is enough), quick results, cost-effectiveness, and ease of interpretation. In addition, this can be easily used in places in bedside or near-to-affected person situations. 38 Rapid serological assays can be utilized for figuring out COVID-19 antigens and COVID-19 antibodies. The ECDC regularly releases up-to-date advisories and encourages the description of the procedure. 39 The European countries union protests that these tests being incorrect and dubious upon analysis and surveillance conveyed skeptical components in the direction of the overall performance of test kits. 40 Furthermore, the proof report from Cassaniti and their team's observation explained a fast check sensitivity underneath 20%, therefore ensuing in a huge scale SARS-CoV-2 false-analysis. 41 Thus, each tool ought to go through a validation method earlier than its scientific application. In light of these types of limitations, it has certain positive points such as low-cost and being trustworthy, providing quantitative facts that are important for longitudinal titter surveillance, professional lab employees overall testing and subjective analysis, and everlasting check on consequences.

These diagnostics can suffice shortages in the laboratory method and maintain strict inner excellent management; however, in the future, the external quality evaluation will be needed. 42 5.2. Molecular Approaches. Many industrial corporations and scientific teams have advanced testing equipment for testing a positive-sense single-stranded ribonucleic acid virus. The virus's whole genetic pattern was placed into the Global Initiative on Sharing All Influenza Database, which provided the records needed for genome molecular detection. The following enlisted molecular approaches are available for COVID-19 diagnosis.

5.2.1. Reverse Transcription-Polymerase Chain Reaction (RT-PCR). Amplification of minute quantities of viral nucleic material in an aggregate of the different nucleic acid mixtures is successfully performed using RT-PCR, and it is presently the mainstream method of COVID-19 detection in respiratory tract samples. Besides, some researchers have applied this to the serum and stool samples as a testing method. 43−45 A current technique has employed the use of salivary samples and is hence considered a noninvasive and secure method for medical workers. 46, 47 In this technique, the reverse transcriptase, initially converts the viral ribonucleic acid into deoxyribonucleic acid using a small primer and the complementary deoxyribonucleic acid, is produced. A fluorescent-tagged probe specific to this deoxyribonucleic acid depicts the amplification of deoxyribonucleic acid in real-time. After several amplification cycles, an electric sign displays the viral cDNA. 48 Normally in the RT-PCR test, 1−2 steps are included. The single-step method contains a single primer tube; the 2-step process makes use of a couple of tubes to run the reactions. In addition, it can store cDNA for quantification of diverse goals with minute starting materials. 49 However, the standard technique for the COVID-19 detection is the singlestep technique as it is far quicker, requires much less sample, has reductions in analysis time, and decreases the chances of pipetting mistakes. Through RT-PCR technology, certain COVID-19 biomarkers, such as nucleocapsid (N), as well as the RNA-dependent RNA polymerase, ORF1b or ORF8, and envelope (E) genes, have been detected in the virus's prognosis. 50−52 Although this technique has significantly been carried out with the detection of COVID-19, some limitations include costly equipment, tedious sample processing, professional personnel, an obstacle in the detection of mutant, and longer time for results. Thus, the development of the RT-PCR technique that can well address these obstacles is a critical issue awaiting solutions.

Amplification. RT-PCR methods have a barrier in the form of the necessity for specialized heat cycling equipment. 53 Isothermal nucleic acid amplification eliminates the requirement for this and enables genome amplification at a constant temperature. Reverse transcription loop-mediated isothermal amplification (RT-LAMP) has been brought as a simple and economical approach to detect COVID-19, which makes use of a chain of 4 target-unique primers to enhance the sensitivity of mixed LAMP and reverse transcription-primer based techniques. Photometry is used to measure turbidity generated by the usage of magnesium pyrophosphate as a byproduct of the amplification mechanism. The photometric or fluorescent assay produces real-time results. The demand for the most effective heating and real-time monitoring steps turns RT-LAMP right into a speedy and touchy device for virus ACS Applied Bio Materials www.acsabm.org Review detection. 54 Presently, Abbott Diagnostics makes use of RT-LAMP for COVID-19 detection as a POC and they use nasal swabs for sample collection. However, it is limited to at least one sample/run. 51,55 Also, the colorimetric LAMP detects viral ribonucleic acid in molecular lysate samples, and it is a better speedy diagnostic method for the detection of RNA of SARS-CoV-2. 52 The different isothermal amplification approaches are known as transcription-mediated amplification (TMA) and may expand particular areas of each RNA and DNA. 51 TMA makes use of T7 RNA polymerase mixed with a retroviral reverse transcriptase enzyme. As a result, each RT-PCR kit and TMA can be performed on Hologic's Panther fusion platform. 56 High-quality results and instantaneous screening of respiratory viruses with signs of SARS-CoV-2 are the primary advantages of Panther's fusion method. Herein, the reaction is initiated by hybridization of the viral ribonucleic acid target with a specific size probe and a second T7 promoter using a magnetic field. Then the reverse transcription of the T7 promoter primer converts ribonucleic acid to a corresponding DNA. Followed by the disintegration of the target ribonucleic acid occurring at the same time as generating a T7 primer together with single-stranded complementary deoxyribonucleic acid from a ribonucleic acid−deoxyribonucleic acid hybrid. Also, T7 ribonucleic acid polymerase is used to supply ribonucleic acid amplicons with the help of extra primers. These amplicons re-enter the TMA system, which at last ends in the era of billions of ribonucleic acid amplicons in a short time. The detection technique employs single-stranded nucleic acid probes that are specific to a fluorophore and a quencher. The real-time hybridization of probes to ribonucleic acid amplicons results in the fluorophore emitting a signal. CRISPR has been advanced for the testing of COVID-19. In CRISPRbased detection approaches, Cas nucleases have been used (Cas12 and Cas13). 57−59 Cas13 has been used as a nonspecific RNase in the detection of RNA/DNA in a technique known as SHERLOCK. 57 Amplification of the aimed ribonucleic acid with the aid of a mixture of T7 and reverse transcription recombinase polymerase amplification (RT-RPA) transcription methods in one step SHERLOCK approach. 60 This activates Cas13, which then cleaves a reporter ribonucleic acid, allowing the fluorescent dye to be released from a quencher. The CRISPR-nCoV has used the SHERLOCK approach in the detection of the COVID-19 genome with exquisite sensitivity in specimens in fifty-two affected persons. 61 Cas12 is a ribonucleic acid-directed DNase that cleaves single-stranded deoxyribonucleic acid from a target collection in a way termed DETECTOR. 58 This method has lately been adopted by several organizations to detect SARS-CoV-2. The first stage in this method is isothermal amplification of viral RNA once it has been converted to DNA. The Cas12 enzyme is then triggered by employing certain target sequences in amplified DNA, and it cleaves a single-stranded DNA reporter to release a fluorescence signal. When combined with fast isothermal amplification techniques, the CRISPR-based methodology can produce quick readouts and sensitive results. They can also be connected to lateral flow assays, which are ideal candidates for simple point-of-care testing. The advantages of this technique include a short turnaround time scale, high sensitivity, and reduced bias generation, but high-cost devices, the need for professional staff, and tedious sampling methods are a few obstacles that must also be taken into account. 62−64 5.2.3. Nucleic Acid Hybridization Using Microarray. Microarray assays have also been used to identify SARS-CoV-2 nucleic acids efficiently and sensitively. The microarray tests begin with the generation of cDNA from viral RNA, which is subsequently identified using precise probes. To load selected cDNAs, solid-phase oligonucleotides constant microarray trays are utilized. In this hybridization method, the existence of viral-specific nucleic acid can be demonstrated. 65 Microarray tests were used to determine the mutations and single nucleotide polymorphisms associated with the SAR-CoV-2 genome. 66 This might help to detect different COVID-19 mutational variants and subtypes more quickly. The MERS coronavirus, like influenza and respiratory syncytial viruses, has been identified using portable microarray chips. 67 Microarray methods that employ a scanner to reveal the hybridization between the probe and the target gene are a quick, sensitive, one-of-a-kind, and accurate method of detection. One can also screen many microbial genes at the same time using this method. Although it can be used to identify numerous samples, this technique does not always allow for the investigation of particular viral genes in restricted samples. 68 5.2.4. Amplicon-Based Metagenomic Sequencing. The amplicon with integrated metagenomic sequencing has been carried out in the testing of COVID-19 and is known as amplicon-based metagenomic sequencing. Metagenomic sequencing was applied to detect the associated microbiome of infected individuals. Amplicon-based sequencing is used to 69 Illumina has furnished a next-generation shotgun metagenomic sequencing method that is now no longer the most effective diagnostics of distinctive coronavirus; however, it can be used to detect different organisms. 51 This procedure can be used beneficially to check the availability of full reference databases, available methods for bioinformatics testing, and the discovery of rare taxa. The main disadvantage of this method is that it is prone to biases in viable population measurement. 70 Various diagnostic approaches are summarized in Table 2 along with advantages. Besides, Tables 3 and 4 enlist some of the devices based on nucleic acid (Table 3) and antibody ( Table 4 ) for detection of SARS-CoV-2 infection.

The microfluidics-based point-of-care (POC) diagnostics are a great addition to the diagnostic devices for the detection of SARS-CoV-2. Certain human illnesses leave detectable biomarkers in our circulatory system. As a result, blood testing has become one of the most widely used methods of disease biomarker analysis. Circulating tumor cells, circulating exosomes, and circulating tumor deoxyribonucleic acid have all recently emerged as new cancer diagnostic markers. 97, 98 The better testing of these biomarkers needs devices that could process a small volume of blood inputs with excessive spatialtemporal accuracy and in an excessive outrun way. Microfluidic-based methods can satisfy these requirements. The combination of various techniques onto microfluidic chips has brought the development of many integrated platforms. Various methodologies that have been commercialized for oncological disease biomarker analysis and tracking have come to be a reality. Current development in genetic material isolation and enhanced detection of microfluidic chips, collectively with isothermal amplification of deoxyribonucleic acid and ribonucleic acid, has assisted circulating tumor deoxyribonucleic acid and pathogen genetic material testing in an integrated microfluidic device. These advancements in the field of microfluidics for disease detection have provided us with a critical toolkit for dealing with growing health issues. In the SARS-CoV-2 pandemic, a number of the present technologies have enabled fast affirmation of the pathogen with the testing kits that provide quick results. Also, the continuing pandemic additionally uncovered the restrictions of the traditional PCR-based methods that require skilled employees in a centralized lab setup. Microfluidics-based diagnostics have the potential to conquer these challenges. 99, 100 During this ongoing SARS-CoV-2 pandemic, aside from the PCR-primarily-based testing, LFA-based rapid assays were extensively used for mass screening of the virus. 101, 102 Multiple agencies have fast evolved and launched merchandise of diagnostic devices that require a microliter of blood and give accurate results. 103, 104 This can significantly supplement and identify the virus in asymptomatic persons and also identify former infections. However, antibody-based testing cannot detect the genetic material and therefore cannot give information about past infections. A quicker, transportable, and specific one-step genetic detection package will accordingly be a critical requirement for the containment of a pandemic. 105 Incorporating microfluidic-based genetic material detection approaches have gone through fantastic technological development in the recent couple of years. 106, 107 There are successful demonstrations of virus detection, genetic material testing, and result visualization on an easy microfluidic-based method. These devices were analyzed for testing genetic material from COVID-19 affected person and offer higher overall efficiency compared to LFA assays and the maximum of that rely on reverse transcriptase LAMP. 108−110 Even though the applicable strategies for process laboratory improvement of devices going on, a few trials were executed to validate the opportunity of making use of those systems for helping modern medical screening. 111 This has been regarded as an unparalleled period for the rising microfluidic-based genetic material testing technology to illustrate their actual functionality and, in addition, enhance their overall efficacy in medical setup for onsite point-of-care testing. The SARS-CoV-2 pandemic has uncovered the restrictions of the modern testing approaches even with the maximum evolved regions of the world. While carrying out analysis, the right way to make ACS Applied Bio Materials www.acsabm.org Review the method quicker is via a high throughput process. The success in growing integrated liquid biopsy systems and microfluidic POCT for infectious diseases has stimulated viable answers. Probably, SARS-CoV-2 will not be the last pandemic that we will experience. Being technologically ready and able to be easily modified for the next pandemic is a lesson we should learn from the contemporary one. There remains a pressing requirement for fast and high throughput SARS-CoV-2 diagnostic strategies as portable POCT systems. 111 Recently, miniature biosensors have shown capacity as an analytical platform due to their specific properties, consistency of results, high sensitivity, reliable specificity, and fast analysis. 112 The design of the microfluidic NIA device showed in Figure 3 .

The developed device showed 98% sensitivity and 100% specificity. They also repurposed glucose test strips for easy and low-cost sampling of blood from an infected person via a simple finger prick. They also found comparable efficacy of the NIA device over an ELISA-based method. 116 A biosensor generally consists of a signal analyzer, transducer, and biological receptor that can detect targets without delay and offers signals in the form of optical and electric indicators. 117, 118 Regular improvement in nanotechnology and engineered intensified systems has decreased the signal-to-noise ratio and improved the detection period for POCT. Biosensor-based target analysis is being considered a possible option for relieving the load on PCR-based techniques, which have been proven to be a superior platform throughout the pandemic. Biosensors-based wearable devices have been employed for easy and quick transmission tracing from sign to tester without the need for a state-of-the-art information analysis system based on understanding. 119−121 Electrochemical biosensors are the most extensively used miniaturized tool that draws a great deal of interest owing to the superiorities consisting of ease, low price, and simplicity of prototype. An electrochemical biosensor generally comprises a custom-designed electrode on which a receptor is placed for time-dependent, precise, and specific target analyte screening. Electrical signal is linked to the presence of the analyte of interest which can be obtained using potentiometric or amperometric methods. 122, 123 Analysis of SARS-CoV-2 was done by Tripathy and their team using an electrochemical biosensor. They used electrodeposited Au nanoparticles over a transducing element. 124 The researchers found that this approach provides quick data gathering, demonstrating its potential as a smart POCT device to lessen the need for large equipment. By introducing a 3-D printing approach, Md. Ali and their team created a 3dimensional reduced-graphene-oxide electrode and integrated it with a microfluidic tool as an electrochemical sensor. 125 Also, 3-D electrodes have been functionalized with viral antigens to allow testing of antibodies against COVID-19. The sensor shows a LOD of 2.8 × 10−15 M. The magnetic beads were combined with a carbon-based electrode to create a small electrochemical sensor for COVID-19 detection. 126 Using magnetic beads, the outer magnetic chamber provides benefits such as increasing preconcentration and eliminating the washing step while maintaining advantages such as sensitive and reliable detection, anti-interference from seasonal H1N1 influenza virus, and so on. One of the current studies uses paper-based electrochemical sensors because of the benefits such as low price, being transportable, and easy disposable format. They print electrodes on paper. Yakoh and their team made the electrochemical tool to test COVID-19 antibodies, and the sensor gives results within 30 min. 127 The paper-based sensor has the potential to revolutionize the POCT platform with the desired sensitivity and property, particularly as they are cost-effective, transportable, and offer simple replacement options. Alafeef and his colleagues developed the detecting probes using a paper-based electrochemical technique for genetic material testing. 128 A portable rapid isothermal amplification (RT-LAMP) device was developed by Ganguli et al. for the detection of SARS-CoV-2 in clinical nasal swab samples. The schematic of an easy and accessible point-of-care device is shown in Figure 5 . The device showed a LOD of 50 RNA copies per microliter and took 30 min for real-time detection of the viral genome. Further, herein additive manufacturing-based 3D cartridge has been used, and the device is coupled with a smartphone-based reader ( Figure  4 ). 108 In another study, a potential microfluidic approach for the detection of antibodies against SARS-CoV-2 has been proposed ( Figure 5A ). The ease of integration of microfluidic platforms with absorbance, fluorescence, and other diagnostic approaches makes them advantageous over conventional diagnostic strategies ( Figure 5 ). 129 With the specific layout of the nanomaterial-based sensing platform, the sensor offers high sensitivity and rapid results within 5 min. Importantly, the sensor tool also provides quantitative target analysis with a linear range of detection from 585.4 copies per μL to 5.854 × 10 7 copies per μL with a susceptibility of 231 copies per μL. To facilitate the quick result for consumer and at-home analysis, the information transmission is another challenge that ought to be considered aside from the electrochemical sensing aspect. Zhao and their team validated that their fabricated sensor may be tailored to a 132 Such a "plug-and-play" way can probably offer a transportable medium for the clients to evaluate the testing result outputs flexibly. The current advancement in electrochemical methods coupled with wireless medium to allow the rapid detection of SARS-CoV-2 is primarily based on huge scale graphene electrodes. 133 Table 5 represents some nanocomposite materials used for the detection of SARS. The validated "SARS-CoV-2 RapidPlex" is cost-effective and reveals high sensitivity, offering multiplexed data on key biomarkers of the SARS-CoV-2 virus, which include viral contamination, immune reaction, and sickness seriousness, with the capacity of home-based prognosis. The broad application of microfluidics in various areas ranging from small valves to biomedical sensors and equipment is shown in Figure 6 . Some of the advantages of various microfluidic devices are listed in Table 6 . The primary difficulty for nucleic acid testing (NAT) is to achieve low-cost, high-throughput, automated nucleic acid (NA) detection from raw samples (e.g., whole blood), which can be solved by fully integrated microfluidic devices that are simple to produce and operate. The completely integrated NA detection is critical, and the sample-in-qualitative-answer-out technique is very simple to implement due to the minimal requirements for NA extraction purity and amplification efficiency. As a result, it is ideal for NA detection with "yes" or "no" answers, for instance, in the case of the Acquired Immune Deficiency Syndrome (AIDS) test and genotyping. NA detection signals on qualitative integrated microfluidic devices mostly comprise colorimetric and fluorescent signals. 134−138 The colorimetric signal of integrated devices can be read with the naked eye without the need for any apparatus, which decreases the cost and resource requirements. In comparison, the limit of detection of fluorescence in integrated devices is lower than that of colorimetric detection. Because of the downsizing of fluorescent readout devices, sample-in-fluorescent-answer-out systems have promising potential for NA qualitative detection. The biggest barrier to commercialization for these high-quality devices is a lack of user-friendliness induced by frequent manual interventions during detection. To match clinic needs, detection sensitivity and stability must be increased further. 139 Sample-in-quantitative-answer-out technology can give precise information for optimum clinic intervention in applications where accurate detection findings are required. A range of quantitative detection methods based on electrochemistry, fluorescence, absorbance, and surface plasmon resonance (SPR) has been proposed to achieve this goal. Fluorescent signals based on dye molecule labels have been widely implemented on point-of-care devices for quantitative readout using image processing software or portable advanced practice providers. Thus, when paired with isothermal amplification techniques, microfluidic devices with fluorescent signal output capacity can achieve sample-to-quantitativeanswer out for NA detection. 138 In contrast to qualitative detection, quantitative detection with higher sensitivity can enable dynamic monitoring and illness categorization, indicating a high potential for extensive clinical use. Real-time isothermal amplification (e.g., real-time LAMP and real-time RPA) techniques based on a periodic acquisition of fluorescence or absorbance signal have been widely used for quantitative results output, similar to traditional real-time PCR for quantitative NA detection. However, today's quantitative procedures necessitate extensive peripheral signal processing systems, which include signal capture, analysis, and transmission modules. As a result, most extant sample-in-quantitative-answer-out solutions take the form of a disposable chip and a reusable device. For practical POC applications, instrument-independent detection is recommended, particularly in resource-constrained settings. As a result, the analytical instrument's downsizing is crucial to boost mobility and save energy, making it ideally suited for field application. Meanwhile, the conversion of computer-based data processing onto mobile terminals would help with commercialization. 139 Existing portable commercially accessible quantitative instruments, such as glucometers and pressure meters, have been introduced for indirect analyte quantification, indicating the tremendous potential to commercialize instrument-free integrated quantitative NA detection. 140, 141 

An artificial intelligence (AI)-aided radiologic analysis system for SARS-CoV-2 such as computed tomography of the chest area is now taken into consideration because of its excessive efficiency in detection of pneumonia-like symptoms. In a metaevaluation of 50 466 patients, as many as 97% of SARS-CoV-2 sufferers had a typical chest CT. 165 Few reviews showed that computed tomography experiments could perceive COVID-19 infection in advance in comparison to viral RT-PCR. 166 In addition, chest computed tomography imaging showed abnormalities in sufferers with moderate or no symptoms. 167 In the computed tomography, maximum sufferers confirmed more than one ground-glass opacity and infiltrating shadows on bilateral lobules and subareas, while in severe condition, pulmonary consolidation also occurred. 168 Because of the rapid spread of the virus, faster result interpretation is required by radiologists to study chest radiographic images. Artificial intelligence is taken into consideration as an aid to help radiologists in SARS-CoV-2 pneumonia analysis. Wang et al. have set up AI algorithms for the correct analysis of SARS-CoV-2 pneumonia primarily based on computed tomography parameters through deep learning technique. 169−171 With help of a massive computed tomography database arising from 3777 infected persons, AI-based algorithms not only help in the treatment of novel pneumonia caused by coronavirus but also can differentiate it from different types of pneumonia from ordinary ones with the support of a mixture of image-primarily based and quantifiable scientific factors. In addition, researchers investigated the connection between imaging functions and scientific biomarkers and integrated it into AI, which helps in viral prognostics. However, using the state-ofthe-art implementation strategies the chest CT scans is not appropriate as a frontline diagnostic. To broaden the diagnostic field to fight against SARS-CoV-2, we should also look to broaden an AI-integrated X-ray or CT as a quick, rapid detecting device for the analysis of pneumonia caused by SARS-CoV-2. 172 Further, AI can be very beneficial with the monitoring and control of SARS-CoV-2, 173 in terms of high detecting accuracy of affected cases, which enhance the survival of significantly unwell patients, presenting the best therapeutic plan, and in the finding of antiviral medicines. Artificial ACS Applied Bio Materials www.acsabm.org Review intelligence-powered robots also can carry out duties for disinfection and aid social distancing; this is typically done without involving humans and for that reason decreasing the risk of infection spread rate in public. With the speedy improvement of the Wi-Fi net era and the growing population of smartphone users, the Mobile Health system has emerged as a valuable technique for healthcare maintenance for humans. An AI-based scientific machine can offer online analytic help to hospitals and clinics in gathering the affected person's data history, symptoms, data of CT imaging, results of laboratory blood tests, or even correlate with the state-of-the-art epidemiology facts (e.g., the state-of-the-art incidence of COVID-19 within the region or traveling history of person), which helps in danger evaluation and perceive the suspected SARS-CoV-2 infection, hence presenting therapeutic decisionmaking choices for the medical care providers. For containment of SARS-CoV-2 in China, greater than 190 public scientific establishments and almost 100 net hospitals throughout China supplied online unfastened session offerings, this keeping off track of affected person touch and direct sanatorium visits, and simultaneously providing care to the affected person while keeping off the danger of nosocomial COVID-19 contamination. Big facts from mobile information, tour data, and social media facts can offer tour styles and information on sufferers with viral contamination, which may be helped to tune affected people near contacts and predict outbreaks. The Allen Institute of Artificial Intelligence, in partnership with leading research studies establishments, has launched an open studies database with weekly information at the SARS-CoV-2 to boost up new studies tasks that provide present-time data. 174 Data software structures inclusive of geographic statistics structures, mapping dashboards, and casemonitoring programs can permit close to real-time tracking of affected person trajectories and social-networking response to a viral transmission. As per the population travel information, danger maps and the trajectories of remarkable transmitters and near contacts can be documented. The structures can screen the temporal and spatial transmission of SARS-CoV-2 and have been proven to be a well-timed and powerful tracking device to tune the virus spreading rate. It can suggest the facts to suitable authorities for immediate responses. 175 The visible and interactive international epidemic map made by the studies group at J H University in the United States of America is presently the maximum extensively employed SARS-CoV-2 epidemic monitoring map. 176 For the epidemiology of SARS-CoV-2 in China, the United States, Canada, and Australia data are gathered. The National Health Commission from China, in association with the industry, launched an "intimate touch measurement" software in February 2020, and through this device, the general public can take a look at if they were or are in near contact with a recognized infected COVID-19 person. However, privatizing issues will not permit this to be carried out in different countries. Telemedicine and eHealth providers seek advice from the usage of computer program structures to offer healthcare distantly. It provides real-time interactive visible, textual input audio, and facts communications to supply scientific-care, session, analysis facts, and remedy. Telemedicine and eHealth have deployed the usage of smartphones, VoIP, and video discussions. 177 Telemedicine restricts publicity of inclined sufferers while concurrently granting healthcare providers the possibility to offer care. Furthermore, telemedicine may permit sufferers to reach their doctors at a distance through the eHealth app inclusive of computer systems as well as mobiles permitting the doctors to see the patients via display screen earlier than they could go to the hospital. 178 This may result in a tremendous decline in pointless disease cases via inspiring self-isolation and social distancing. 179, 180 Even though telemedicine can begin with cell smartphone consults, different laptop technology inclusive of webcam-enabled nonpublic computer systems, smartphones, and excessive-pace net may be hired to offer healthcare to sufferers. While the face-to-face session is certainly critical for a medical doctor analyzing an affected person, it is far untenable at some stages in pandemics. Leite et al. encouraged outpatients inclusive of the ones now no longer infected with the SARS-CoV-2 virus, especially the excessive-sensitive categories (pregnant women, older peoples, etc.), to use telemedicine as it could offer secure and handy options as a remedy without the need to visit the care center. 181−183 IoT integrated health care applications aid sufferers to be handled at their homes, with a better degree of care, also aid supplies of data digitally and help physicians to provide care to the individual under emergency situations through 911 calls, lowering the demand for movement to the emergency unit. This digital emergency facility could help to allocate works among the specialist scientific practitioners. 184 Mobile health entails the usage of appropriate tools and hand-held gadgets geared up to control hospital-based therapy operations in terms of scientific facts and availing experience of earlier infected/diseased conditions. This software can be utilized to get the right scientific statistics, which would be utilized by doctors to aid dissemination of such statistics with different scientific practitioners in real-time. 177 Self-quarantine and social isolation are being assessed by the use of social networking applications. Even though eHealth structures cannot update interaction on a one-on-one basis, they offer ease for folks who experience loneliness and depression because of the live-at domestic order/lockdown. These programs may be hooked up and utilized in smartphones having different OS. It can be assessed using the laptop software program in Windows structures and Apple MacBook among others. Medical programs contain applications that offer healthcare in both synchronous and asynchronous manners to patients. The eHealth structures provide health care manual and assets especially to sufferers dwelling in undeveloped regions wherein health care is inadequate. Besides, eHealth platforms enable sufferers to get suggestions from faraway physicians during catastrophe or emergency. For instance, one scientific program called K Health provides Doctor on Demand and Primary Care, while another known as Teladoc can be downloaded on mobile application manager and used for health care management. These scientific programs offer patients to certified physicians for nonemergency health issues too and are encouraged via way of means of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant in the US. 185 Contact tracing is a critical step for society to control the spread of COVID-19. Currently, touch tracing programs are getting used throughout the world. As an example, the Singaporean authorities launched a cell software TraceTogether, advanced to assist fitness officers in monitoring infected men or women and who they will have been in touch with. In Israel, a regulation program led the authorities to tune the facts of people with suspected contamination. In Taiwan, health care establishments via smartphone track and informed people for quarantine. 186 Health and health programs are currently employed as a result of quarantine and social isolation that promote sedentary behavior and decreased bodily interest, which is a kind of health burden for a population that spends 60% of its time involved in sluggish activities. Therefore, the usage of fitness and health programs has the potential to lessen the ill effect of sedentary behaviors, enhance mental fitness, and maintain the drowsing habits. Software MyFitnessPal, which gives a diet regime and calorie tracker, is getting used to offer the advantage of healthy life. 185 

PROMISE TO DEAL WITH FUTURE PANDEMICS Regular disease monitoring in viral illnesses is essential for being capable of dealing with pandemics and reducing the social and economic health burden of the country. Nations that have accomplished well in dealing with SARS-CoV-2, for example, South Korea and Vietnam, had precise infection monitoring systems. 187 India had made a fairly powerful "Integrated Diseases Surveillance Program (IDSP)", that offered information about the infectionoutbreaks; however, it was not presenting such information after February. To suffice the need, the Indian Government commenced a new portal for SARS-CoV-2 update. 188 A powerful ailment surveillance system reviews not only surprising uncommon health incidences but also additionally routine records on viral sequence from each health care provider. As a result, every usual burst of fever and symptoms raises a local alarm, allowing for a well-timed and sufficient response. These indications and symptoms-based evaluations inform the local bodies, which must be followed up with confirmation tests performed in a lab network. In larger metropolitan regions, the IDSP's symptombased statistics detect afflicted individuals' death and are useful in the early identification of recent chains of contamination and adverse reaction to them. A reliable digital illness monitoring tool that is seamlessly integrated with health management information systems is also an important aspect of building durability. The actual health facts furnished through such a method are worthwhile but not best for presenting early signs of a deadly disease; however, they provide additional support for monitoring the spread of the epidemic, forecasting, and getting ready the care portal for the surge. 189 It also identifies areas where access to certain vital health services is needed, which needs to be addressed as soon as possible. However, there are several inadequacies in current health management data architectures. The lack of interoperability between the IDSP's virtual platform and the HMIS is one issue. In addition, in most states, the HMIS no longer has personal area information. Furthermore, neither the disease surveillance system nor the HMIS gathers information that may be disaggregated for understanding sickness relationships with inequity such as migrant workers, the elderly, or other disadvantaged populations who could be a source of disease transmission. Countries that are exceptionally good in health information systems, just like the National Health Services (NHS) in the United Kingdom, had provided greater awareness of the COVID-19. They had started initial research of mode of transmission of viral infection, from their wellmaintained infected person information, and use this to perceive the spreading chains and contact tracing for the SARS-CoV-2 mortality/morbidity rate of their country. 190 There is also a requirement to link HMIS with data from other fields. For example, there is a need to link healthcare data with environmental and weather-change measurements, as well as predictions of extreme weather, to see how this affects each chronic pollution and pandemic outbreak. 191 Similarly, we additionally require integration of financial information with the wellbeing system, as a model, the effect of the huge variety of economic occasions like modifications in trade coverage or economic disaster just like the international economic disaster of 2009, on the health effects and health systems performance. 192 One of the demanding situations we are facing in those records is associated with the time-bound of the data series and problems of integration. The health records regularly lag 12 months behind, while monetary records are more on time. 193 While handling emergencies, the facts needed can be exceptional from the information needed for ordinary purposes. 194 To cope with these problems, there is huge demand for funding in HR training, modern and handy ways, if possible open supply, and precise governance. This will be visible in Germany where a lab had been prepared to make greater than 50 000 tests mid February; even if COVID-19 spread into a large part of China, they have a strong initial forecasting system, that had been "maximally equipped". Among the essential and least mentioned factors of constructing robust health care systems is the capacity to control international and native chains of infection for critical therapeutic products. One indicator of this is that every country's public health infrastructure must have reliable procurement and distribution networks. In India, a few states, such as Kerala, Tamil Nadu, and Rajasthan, have systems in place; nevertheless, logistics may be an issue for others. Such home capability will offer enough portions of essential drug treatments, diagnostics, devices, vaccines, and a private protecting system that the United States requires. SARS-CoV-2 has proven to us that during a disaster, international supply chains are unreliable and unfair. The European countries and the United States are possible to go into superior marketing dedications with the intention to nook supplies or medicinal drug even earlier than they're made. But India has a popularity of being the drugstore of the growing international world due to the fact that it has the capacity to manufacture all critical drugs and diagnostics that are now no longer present in India, in accordance with the complete international requirement. However, this may have a long way to be fulfilled and need investment in from developed countries. We should apprehend what went wrong in the course of this COVID-19 pandemic and why we needed to import nearly all of the medical equipment, tablets, and personal protective kits that the United States required. This might assist us to plan to quickly reconstruct our local capability in manufacturing and domestic productivity of critical clinical items. 192, 195 Health system response in the course of Ebola illnesses in Liberia turned into praise considering that they supplied loose offerings for human beings without Ebola. Public coverage in India to take care of all sufferers coming to hospitals is difficult to handle due to deficiency of consumables and basic amenities. One of the primary desires of public health structures is to make certain economic safety. In addition, the cost of health care during lockdowns and unemployment affected the normal life of millions of people. The economic safety toward the cost of medical care is that almost all operating human beings require a better stage of public health care funds than presently allocated. 197 Given that it commonly takes 1 to 2 weeks for human B cells to supply and produce generally traceable antibodies into the serum after viral infection; hence, there may be fewer serum antibodies in the early phase of SARS-CoV-2 infection, which can provide false-negative results in the case of LFIA. Therefore, COVID-19, proteins, and viral genome detection are considered better techniques for giving direct initial evidence of COVID-19 infection. 198 Finding these biomarkers will be the most effective method for early POC screening of SARS-CoV-2 sufferers. However, the viral proteins and viral particles are very little in the body fluids of SARS-CoV-2 patients. 199−201 Therefore, novel, promising, excessive-sensitivity POCT immunosensors, which include NIR emitting nanoparticles, magnetic nanoparticle-based LFAs, and electrochemical biosensors, for detection of SARS-CoV-2 antigen, antibodies, and virus particles, are the need of the hour. While point-of-care biosensors are broadly available, further enhancements are needed to deliver high throughput results. The current common diagnostic kits contain IgG test strips and take less assay time; however, their sensitivity and specificity needed to be improved. 202 To improve detection efficiency, a few sensitivity enhancement techniques must be applied to the biosensors such as fluid dynamic management, enzyme-based signal improvement techniques, and sample pretreatment strategies. 203−205 To enhance detection sensitivity, the functionality of multiplexing is vital, which also improves assay productivity. 206 In particular, the clubbing of each IgG/ IgM and RNA test could provide the information on the initial and later stages of SARS-CoV-2 infection, providing accurate and reliable results. 207 Also, to make the testing assay easier to perform, multiple processing steps starting from sample pretreatment to signal detection must be incorporated into a single biosensor. Importantly, recent research has integrated sample-to-answer techniques right into single biosensors to find antibodies and genetic material of the virus, which can be performed for the detection of SARS-CoV-2. 208 Moreover, integrating a sample collector in the biosensors could make it greater user-friendly. For example, incorporating a microneedle for the painless series of blood samples can make the biosensor less invasive and could additionally lessen affected person anxiety and stress. 209 Since blood samples can be taken with a single push of a button, the usage of biosensors needs little skill or education. Besides blood testing sensors, greater point-ofcare biosensors are being evolved to detect the SARS-CoV-2 virus in saliva. 210, 211 This method is noninvasive, and the sample is simple to acquire transport and test. Future research must also be cognizant of developing transportable and miniaturized biosensors. 212 Storing reagents on-chip could be most suitable to cut off the requirement for storage units, for example, refrigerator and freezer. 213 Moreover, integrating a transportable electric temperature control unit could strengthen assay functionality, mainly for genetic material assessments kits that needed a heater for amplification. 214, 215 This feature is beneficial specifically in low-resource settings. Data quantification is likewise vital as it should be compared to assess the sufferers' health conditions. 216 It will be done through growing telephone applications that permit data characterization in remote settings while permitting information storage to tune sufferers' health status. Employing Internet-of-Things (IoT) provides sufferers' test outcomes with medical care workers and allows evaluation and monitoring of affected person fitness statistics for onsite real-time health care monitoring. 217, 218 In summary, the easy, fast, less costly, and transportable biosensors have shown potential in point-of-care testing in this pandemic time. Given that the virus may be transmitted to a healthy person from a patient, the improvement of homebased point-of-care biosensors is of supreme significance to permit self-assessment and instantaneously self-quarantine as soon as a person is tested positive to keep away from spreading the virus. 207 It is envisioned that the emerging point-of-care biosensors will be made on a huge scale for mass testing of SARS-CoV-2 cases to combat the pandemic. Future lockdowns are likely to come. Information technology could be capable of supporting the clinical factors, vaccination statistics, and therapeutic strategies directly; also we can share knowledge, experiences, and technology to tackle futuristic pandemics. It is very difficult to set up a worldwide common data management platform for public health records because of numerous factors which include technical, geopolitical, and moral challenges. To this level, statistics data banks can at the least assist endorsing and constructing a countrywide common health data portal for society health records sharing. Moreover, COVID-19 investment opportunities, to get economic aid to place several thoughts into practice would help to manage economic losses. For example, the United States National Science Foundation and National Institutes of Health have presented projects that provide financial aid to address demanding situations due to the coronavirus. In addition, more college students with statistics and data science backgrounds can be employed as interns. Because a large number of small organizations in ACS Applied Bio Materials www.acsabm.org Review industries which include tourism, food service, and commercial stores are being hit toughest through the pandemic, information technology faculty should gather students, as a part of mini commercial enterprise proprietors. This could assist in shaping statistics data collection and management in the pandemic. Several colleges are supporting this and mentoring micro commercial enterprise proprietors on deploying virtual technology to cope with the challenges of commercial enterprise continuity. 219 Some professors have been involved in virtual answer improvement projects, for example, tackling misinformation and arranging activities, which include online hackathons to acquire human beings with numerous talents to paintings on solutions to combat SARS-CoV-2. 220,221 At last, a number of the evolved technology and alertness for this pandemic might also be beneficial after the COVID-19 ends for better preparedness of futuristic pandemics. 222 The involvement of computational approaches can be useful for future scientific settings and could produce a big technological revolution to treat human healthassociated problems in a real-time manner. Artificial intelligence avoids human emotional problems, religion and ethical faith, and fatigue. 223 Optimal decision-making intelligence and nonstop upgrading through networks and deep learning could be remarkable gear to help clinical doctors with the analysis and in finding the disease in a brief time. 224 Artificial intelligence-based deep learning algorithms have lots of boundaries at small and large levels for the medical care area. These bottlenecks consisting of unregulated algorithms, unsupervised studying implementations, affected the personal data confidentiality, and records set size, call for big interest toward human-computer interface and the usage of AI. 223 The reproducibility of diagnostic tests is one of the main boundaries in molecular drug findings that takes a few years to release powerful components in the marketplace after scientific research. 225 Analyzing a big set of complex and numerous health care records should be controlled via way of means of the evaluation of large records and ML gear to decrease hassle and false-positive data. 226 Lastly, AI itselfsufficient and cannot over-ride human involvement. AI in the clinical professional can reap a particular remedy overall performance and identify the best diagnostic at the very best possible level.

The article deals with the impact of COVID-19 first, second, and third wave along with the symptoms and precautions that are being addressed. The evolution of diagnostic methods from conventional to more sophisticated microfluidics and AI integrated processes has been discussed. The rapid detection methods using microfluidics technology and biosensors kept the health monitoring system growing at a very convenient pace. The use of machine learning and artificial intelligence coupled together with the latest technologies of biosensors and mobile phones made it possible for general human beings to take care of themselves, be aware of the environment, and also helped them to get a lot of information on the spread of disease and its preventive controls. The vaccines are still gaining some exposure to the use of IoT and maintaining a database so that a track of vaccinated people can be maintained. 

The fellowship provided by DST under the DST-WOS-B scheme to A.P. is duly acknowledged.

A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome

of Novel Coronavirus-Infected Pneumonia

Evolving Epidemiology and Transmission Dynamics of Coronavirus Disease

Clinical and Immunological Assessment of Asymptomatic SARS-CoV-2 Infections

COVID-19 Re-Infection by a Phylogenetically Distinct SARS-Coronavirus-2 Strain Confirmed by Whole Genome Sequencing

Genomic Evidence for Reinfection with SARS-CoV-2 : A Case Study

Antibody-Dependent Enhancement of Coronavirus

Immunoinformatics and Molecular Modeling Approach to Design Universal Multi-Epitope Vaccine for SARS-CoV-2

Rapid Review The Psychological Impact of Quarantine and How to Reduce It: Rapid Review of the Evidence

SARS Control and Psychological Effects of Quarantine

Prevalence and Predictors of Posttraumatic Stress Symptoms in Utility Workers Deployed to the World Trade Center Following the Attacks of

Risk and Resilience in Canine Search and Rescue Handlers after 9/11

The COVID-19 Pandemic Brings a Second Wave of Social Isolation and Disrupted Services

Main Differences between the First and Second Waves of COVID-19 in Madrid

What Is the Difference between the First and the Second/Third Wave of Covid-19? -German Perspective

Third Wave of COVID-19 in Madrid

Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern; WHO

Algeria's Preparedness for Omicron Variant and for the Fourth Wave of COVID-19

Omicron Variant of the SARS-CoV-2: A Quest to Define the Consequences of Its High Mutational Load

Three Waves Changes, New Variant Strains, and Vaccination Effect against COVID-19 Pandemic

Current Approaches in Laboratory Testing for SARS-CoV-2

Laboratory Testing Methods for Novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)

Laboratory Diagnosis of SARS-CoV-2: Available Approaches and Limitations

Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives

Cold Plasma, a New Hope in the Field of Virus Inactivation

Commercialized Diagnostic Technologies to Combat SARS-CoV2: Advantages and Disadvantages

Point-Counterpoint: Should We Be Performing Metagenomic next-Generation Sequencing for Infectious Disease Diagnosis in the Clinical Laboratory

Benefits and Limitations of Serological Assays in COVID-19 Infection

Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR. Radiology

Lateral Flow Assays towards Point-of-Care Cancer Detection: A Review of Current Progress and Future Trends

Capillary as a Liquid Diode

Estimating the Asymptomatic Proportion of Coronavirus Disease

Eurosurveillance.; European Centre for Disease Prevention and Control (ECDC)

Italian Society of Colorectal Surgery Recommendations for Good Clinical Practice in Colorectal Surgery during the Novel Coronavirus Pandemic

Types of Assays for SARS-COV-2 Testing: A Review. Lab Medicine

Saliva-Based Pcr Tests for Sars-Cov

Twenty-Five Years of Quantitative PCR for Gene Expression Analysis

Real-Time PCR for MRNA Quantitation

Diagnostic Technology Landscape: Efficient Data Sharing Drives Diagnostic Development. Frontiers in Public Health

Rapid Molecular Detection of SARS-CoV-2 (COVID-19) Virus RNA Using Colorimetric LAMP

Loop-Mediated Isothermal Amplification of DNA

Development and Evaluation of a Novel Loop-Mediated Isothermal Amplification Method for Rapid Detection of Severe Acute Respiratory Syndrome Coronavirus

In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends. Diagnostics

Laboratory Diagnosis of Emerging Human Coronavirus Infections-the State of the Art. Emerging Microbes and Infections

CRISPR-Cas12a Target Binding Unleashes Indiscriminate Single-Stranded DNase Activity

CRISPR-Cas12a-Assisted Nucleic Acid Detection

Integrated Lateral Flow Recombinase Polymerase Amplification (MI-IF-RPA) Assay for Rapid

Detection

Current Status of Laboratory Diagnosis for Covid-19: A Narrative Review. Infection and Drug Resistance

Design and Fabrication of 3-Dimensional Helical Structures in Polydimethylsiloxane for Flow Control Applications. Microsystem Technologies

Digital CRISPR/Cas-Assisted Assay for Rapid and Sensitive Detection of SARS-CoV-2

Comprehensive Detection and Identification of Seven Animal Coronaviruses and Human Respiratory Coronavirus 229E with a Microarray Hybridization Assay

Development of a Single Nucleotide Polymorphism DNA Microarray for the Detection and Genotyping of the SARS Coronavirus

Initial Performance Evaluation of a Spotted Array Mobile Analysis Platform (MAP) for the Detection of Influenza A/B, RSV, and MERS Coronavirus

Nucleic Acid-Based Approaches for Detection of Viral Hepatitis

Amplicon-Based Detection and Sequencing of SARS-CoV-2 in Nasopharyngeal Swabs from Patients with COVID-19 and Identification of Deletions in the Viral Genome That Encode Proteins Involved in Interferon Antagonism

WHO Emergency Use Assessment Coronavirus Disease

Xpert Xpress SARS-CoV-2 EUL Number: EUL-0511-070-00 Outcome: Accepted; WHO, 2020. (73) GeneXpert System; Cepheid

Rapid Assessment of the GenMark EPlex SARS-CoV-2 Test

The ePlex System: The True Sample-to-Answer Solution

Development of an Automatic Integrated Gene Detection System for Novel Severe Acute Respiratory Syndrome-Related Coronavirus (SARS-CoV2)

COVID-19) Research Testing Solutions; Luminex

LamPORE Assay; Nanopore

Diagnosis of SARS-CoV-2 Infection with LamPORE, a High-Throughput Platform Combining Loop-Mediated Isothermal Amplification and Nanopore Sequencing

Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing

EasyNAT Novel-Coronavirus (2019-nCoV) Real-Time Molecular Diagnostic System; USTAR Biotechnologies (Hangzhou) Ltd., 2021

BinaxNOW COVID-19 Ag Card Home Test -Instructions for Use

Taking COVID-19 Testing to a New Level

COVID-19 Serology and Molecular Tests; Wantai

Battling coronavirus_Beijing hot view biology

The LumiraDx SARS-CoV-2 Ag Test is a rapid microfluidic immunoassay detecting SARS-CoV-2 antigen; LumiraDx

Evaluation of Three Immunochromatographic Tests for Rapid Detection of Antibodies against SARS-CoV-2

Antibody Testing; Luminex Corporation

IgM and IgG Antibody Combo Test Kit Instructions for Use For Use under an Emergency Use Authorization (EUA) Only For Prescription Use Only For in Vitro Diagnostic Use Only

CoV-2 IgM and IgG Combo Test Kits

COVID-19 Response

Ellume COVID-19 Home Test Product Overview for Healthcare Professionals

Biosensor-Based Diagnostic Approaches for Various Cellular Biomarkers of Breast Cancer: A Comprehensive Review

Microfluidic Detection of Human Diseases: From Liquid Biopsy to COVID-19 Diagnosis

Optimization of laser machining process for the preparation of photomasks, and its application to microsystems fabrication

Molecular Diagnosis of COVID-19: Current Situation and Trend in China (Review). Experimental and Therapeutic Medicine

Cancer Liquid Biopsy Using Integrated Microfluidic Exosome Analysis Platforms

Dynamic Profile for the Detection of Anti-SARS-CoV-2 Antibodies Using Four Immunochromatographic Assays

Microfluidic Immunoassays for Sensitive and Simultaneous Detection of IgG/IgM/Antigen of SARS-CoV-2 within 15 min

Bioengineering Tools to Speed up the Discovery and Preclinical Testing of Vaccines for SARS-CoV-2 and Therapeutic Agents for COVID-19

A Rapid and Label-Free Platform for Virus Capture and Identification from Clinical Samples

Labon-a-Chip" to Detect Viruses -Current Challenges and Future Perspectives

Rapid Isothermal Amplification and Portable Detection System for SARS-CoV-2

RT-LAMP for Rapid Diagnosis of Coronavirus SARS-CoV-2

A Colorimetric RT-LAMP Assay and LAMP-Sequencing for Detecting SARS-CoV-2 RNA in Clinical Samples

Diagnostic Approaches: Different Roads to the Same Destination

31, 97−105

The Impact of Biosensing in a Pandemic Outbreak: COVID-19

Opportunities and Challenges for Biosensors and Nanoscale Analytical Tools for Pandemics: COVID-19

Biosensor Based Advanced Cancer Diagnostics : From Lab to Clinics

Scope of Biosensors, Commercial Aspects, and Miniaturized Devices for Point-of-Care Testing from Lab to Clinics Applications. Biosensor Based Advanced Cancer Diagnostics 2022

A High-Throughput Microfluidic Nanoimmunoassay for Detecting Anti-SARS-CoV-2 Antibodies in Serum or Ultralow-Volume Blood Samples

Development of Point-of-Care Biosensors for COVID-19

Clinical Decision Support Tool and Rapid Point-of-Care Platform for Determining Disease Severity in Patients with COVID-19

Biosensors for Managing the COVID-19 Cytokine Storm: Challenges Ahead

Advancement in Biogenerative Engineering to Combat Shortage of Organs and Bioapplicable Materials

Accurate, Point-of-Care COVID-19 Pandemic Diagnosis Enabled through Advanced Lab-on-Chip Optical Biosensors: Opportunities and Challenges

Electrochemical Detection of Viruses and Antibodies: A Mini Review

Disposable Electrochemical Sensors: A Mini Review

Label-Free Electrochemical Detection of DNA Hybridization: A Method for COVID-19

Sensing of COVID-19 Antibodies in Seconds via Aerosol Jet Nanoprinted Reduced-Graphene-Oxide-Coated 3D Electrodes

An Electrochemical SARS-CoV-2 Biosensor Inspired by Glucose Test Strip Manufacturing Processes

Paper-Based Electrochemical Biosensor for Diagnosing COVID-19: Detection of SARS-CoV-2 Antibodies and Antigen

Ultrasensitive, and Quantitative Detection of SARS-CoV-2 Using Antisense Oligonucleotides Directed Electrochemical Biosensor Chip

Nanotechnology-Based Approaches for the Detection of SARS-CoV-2

A Lab-on-a-Chip Platform for Integrated Extraction and Detection of SARS-CoV-2 RNA in Resource-Limited Settings

Microfluidic-Based Virus Detection Methods for Respiratory Diseases

Ultrasensitive Supersandwich-Type Electrochemical Sensor for SARS-CoV-2 from the Infected COVID-19 Patients Using a Smartphone

SARS-CoV-2 RapidPlex: A Graphene-Based Multiplexed Telemedicine Platform for Rapid and Low-Cost COVID-19 Diagnosis and Monitoring

Microfluidic Rapid and Autonomous Analytical Device (MicroRAAD) to Detect HIV from Whole Blood Samples

Rapid detection and typing of live bacteria from human joint fluid samples by utilizing an integrated microfluidic system

A microdevice for rapid, monoplex and colorimetric detection of foodborne pathogens using a centrifugal microfluidic platform

Fabrication of a foldable all-in-one point-of-care molecular diagnostic microdevice for the facile identification of multiple pathogens

Fully Integrated Microfluidic Devices for Qualitative, Quantitative and Digital Nucleic Acids Testing at Point of Care

Commercialization of Microfluidic Point-of-Care Diagnostic Devices. Advanced Microfluidics-Based Point-of-Care Diagnostics 2022

Integrating Target-Responsive Hydrogel with Pressuremeter Readout Enables Simple, Sensitive, User-Friendly, Quantitative Point-of-Care Testing

An Exploration of Nucleic Acid Liquid Biopsy Using a Glucose Meter

Dual-Functional Plasmonic Photothermal Biosensors for Highly Accurate Severe Acute Respiratory Syndrome Coronavirus 2 Detection

Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor

Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene Targeted Antisense Oligonucleotide Capped Plasmonic Nanoparticles

Rapid Enumeration of CD4 + T Lymphocytes Using an Integrated Microfluidic System Based on Chemiluminescence Image Detection at Point-of-Care Testing

Sensitive Detection of Single-Cell Secreted H2O2 by Integrating a Microfluidic Droplet Sensor and Au Nanoclusters

Cellphone-Enabled Microwell-Based Microbead Aggregation Assay for Portable Biomarker Detection

Photonic Lab-ona-Chip for Rapid Cytokine Detection

Real-Time CRP Detection from Whole Blood Using Micropost-Embedded Microfluidic Chip Incorporated with Label-Free Biosensor

Microfluidic Device for Novel Breast Cancer Screening by Blood Test Using MiRNA Beacon Probe

Rapid and Label-Free Detection of Interferon Gamma via an Electrochemical Aptasensor Comprising a Ternary Surface Monolayer on a Gold Interdigitated Electrode Array

Immunosensor for the Ultrasensitive and Quantitative Detection of Bladder Cancer in Point of Care Testing

Multiplex Surface Plasmon Resonance Imaging-Based Biosensor for Human Pancreatic Islets Hormones Quantification

Detection of Early Stage Prostate Cancer by Using a Simple Carbon Nanotube@paper Biosensor

An Ultrasensitive Label Free Nanobiosensor Platform for the Detection of Cardiac Biomarkers

A Facile Method for Urinary Phenylalanine Measurement on Paper-Based Lab-on-Chip for PKU Therapy Monitoring

Integration of Paper and Micropipette Tip to Build a "Sample-in, Answer-out" Point-of-Care Device

An Electrochemiluminescence Cloth-Based Biosensor with Smartphone-Based Imaging for Detection of Lactate in Saliva

Reconfigurable Flow Switch for Paper Microfluidics Based on Selective Wetting of Folded Paper Actuator Strips

Point-of-Care Detection of Extracellular Vesicles: Sensitivity Optimization and Multiple-Target Detection

A New Lateral-Flow Immunochromatographic Strip Combined with Quantum Dot Nanobeads and Gold Nanoflowers for Rapid Detection of Tetrodotoxin

Lateral Flow Assay with Pressure Meter Readout for Rapid Point-of-Care Detection of Disease-Associated Protein

A New Lateral Flow Strip Assay (LFSA) Using a Pair of Aptamers for the Detection of Vaspin

Development of a Functional Point-of-Need Diagnostic for Myeloperoxidase Detection to Identify Neutrophilic Bronchitis

Clinical Characteristics of Hospitalized Patients with SARS-CoV-2 Infection: A Single Arm Meta-Analysis

Development and Clinical Application of a Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis

The Epidemiological and Radiographical Characteristics of Asymptomatic Infections with the Novel Coronavirus (COVID-19): A Systematic Review and Meta-Analysis

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)

Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography

Artificial Intelligence-Enabled Rapid Diagnosis of Patients with COVID-19

COVID-19 in Early 2021: Current Status and Looking Forward

Silico Analysis for the Repurposing of Broad-Spectrum Antiviral Drugs against Multiple Targets from SARS-CoV-2: A Molecular Docking and ADMET Approach

Digital Technology and COVID-19

Artificial Intelligence and Machine Learning to Fight Covid-19

Geographical Tracking and Mapping of Coronavirus Disease COVID-19/Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Epidemic and Associated Events around the World: How 21st Century GIS Technologies Are Supporting the Global Fight against Outbreaks and Epidemics

An Interactive Web-Based Dashboard to Track COVID-19 in Real Time

Exploring the Potentials of Telemedicine and Other Non-Contact Electronic Health Technologies in Controlling the Spread of the Novel Coronavirus Disease

COVID-19 and Telemedicine: Immediate Action Required for Maintaining Healthcare Providers Well-Being

Salvador Verges, A.; López Seguí, F. Telemedicine in the Face of the COVID-19 Pandemic

Telemedicine in the Era of the COVID-19 Pandemic: Implications in Facial Plastic Surgery

Telehealth for Global Emergencies: Implications for Coronavirus Disease 2019

The Role of Telemedicine to Control COVID-19. Archives of Clinical Infectious Diseases

Flattening the Infection Curve -Understanding the Role of Telehealth in Managing COVID-19

Virtually Perfect? Telemedicine for Covid-19

15 Smartphone Apps for Older Adults to Use While in Isolation During the COVID-19

Contact Tracing Mobile Apps for COVID-19: Privacy Considerations and Related Trade-Offs

Coronavirus Cases Have Dropped Sharply in South Korea. What's the Secret to Its Success?

Health Systems Preparedness for COVID

S91−S93

Emergency Preparedness and Public Health Systems. Lessons for Developing Countries

Risk Factors for SARS-CoV-2 among Patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre Primary Care Network: A Cross-Sectional Study

Planning Adaptive Health Systems: The Climate Challenge. The Lancet Global Health

Financial Crisis, Austerity, and Health in Europe. The Lancet

Austerity: A Failed Experiment on the People of Europe

The Role of Surveillance in Facilitating New Diplomacy during the 2009−2010 H1N1 Pandemic. Health and Place

Role of Microfluidics-Based Point-of-Care Testing (POCT) for Clinical Applications. Advanced Microfluidics-Based Point-of-Care Diagnostics 2022

Leveraging 3D Printing Capacity in Times of Crisis: Recommendations for COVID-19 Distributed Manufacturing for Medical Equipment Rapid Response

Microfluidic Devices for Sample Preparation and Rapid Detection of Foodborne Pathogens

Transcriptional Difference between SARS-COV-2 and Other Human Coronaviruses Revealed by Sub-Genomic RNA Profiling

Clinical Characteristics of COVID-19 Patients with Digestive Symptoms in Hubei, China: A Descriptive

Potential False-Negative Nucleic Acid Testing Results for Severe Acute Respiratory Syndrome Coronavirus 2 from Thermal Inactivation of Samples with Low Viral Loads

Evaluation of a COVID-19 IgM and IgG Rapid Test; an Efficient Tool for Assessment of Past Exposure to SARS-CoV-2

Polydimethylsiloxane-Paper Hybrid Lateral Flow Assay for Highly Sensitive Point-of-Care Nucleic Acid Testing

An Enzyme-Amplified Lateral Flow Strip Biosensor for Visual Detection of MicroRNA-224

Improved Sensitivity of Lateral Flow Assay Using Paper-Based Sample Concentration Technique

Multiplexed Lateral Flow Biosensors: Technological Advances for Radically Improving Point-of-Care Diagnoses

Emerging Point-of-Care Biosensors for Rapid Diagnosis of COVID-19: Current Progress, Challenges, and Future Prospects

Advances and Challenges of Fully Integrated Paper-Based Point-of-Care Nucleic Acid Testing

Microneedle-Based Device for the One-Step Painless Collection of Capillary Blood Samples

Saliva Liquid Biopsy for Point-of-Care Applications. Frontiers in Public Health

Point-of-Care Biosensor-Based Diagnosis of COVID-19 Holds Promise to Combat Current and Future Pandemics

High Throughput Molecularly Imprinted Polymers Based Electrochemical Nanosensors for Point-of-Care Diagnostics of COVID-19

Advances in Reagents Storage and Release in Self-Contained Point-of-Care Devices

Plug-and-Power" Point-of-Care Diagnostics: A Novel Approach for Self-Powered Electronic Reader-Based Portable Analytical Devices

A Fully Disposable and Integrated Paper-Based Device for Nucleic Acid Extraction, Amplification and Detection

Point-of-Care Testing Based on Smartphone: The Current State-of-the-Art

Automatic Smartphone-Based Microfluidic Biosensor System at the Point of Care

Combining Point-of-Care Diagnostics and Internet of Medical Things (IOMT) to Combat the Covid-19 Pandemic

The Use of Digital Technologies by Small and Medium Enterprises during COVID-19: Implications for Theory and Practice

The COVID-19 Virtual Idea Blitz: Marshaling Social Entrepreneurship to Rapidly Respond to Urgent Grand Challenges

From Fighting COVID-19 Pandemic to Tackling Sustainable Development Goals: An Opportunity for Responsible Information Systems Research

COVID-19 Tech Will Expand Surveillance State in China

Artificial Intelligence Can Improve Decision-Making in Infection Management

Machine Learning and Prediction in Medicine  Beyond the Peak of Inflated Expectations

Towards Reproducible Computational Drug Discovery

Big Data and Machine Learning Algorithms for Health-Care Delivery

e262−e273